decisionhealth Newsletters, Part B News - 2020 Issue 12 (December)
Opioid treatment expands, with Narcan payable, requirements in AWV, IPPE
Subscribe or sign in to view the full article.
Article Overview
This article explains recent CMS final-rule changes tied to opioid treatment programs and preventive care documentation. It is relevant to billing, coding, compliance, and clinical operations teams that follow Medicare policy updates affecting opioid use disorder services, naloxone-related coverage, provider enrollment processes, and required screening topics in the IPPE and AWV. The coverage also references the SUPPORT Act and discusses how these policy changes fit within broader opioid treatment and prevention efforts.
Why This Topic Matters
The update affects Medicare payment and administrative workflows for opioid treatment programs and preventive visits. It may influence how organizations handle coverage, enrollment documentation, and screening-related requirements under current CMS policy.
What You Will Learn
- How CMS updated Medicare policy for opioid treatment program services
- What types of naloxone-related payment changes were finalized
- How enrollment form handling for opioid treatment programs was addressed
- What preventive visit screening requirements were added or clarified
- How the SUPPORT Act is connected to these policy changes
Who Should Read This
- Medical coders
- Billing staff
- Compliance professionals
- Revenue cycle teams
- Opioid treatment program administrators
- Primary care practices
- Medicare policy analysts
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com